“We’re targeting a company-wide breakeven by 2028,” said Mike Bell, CFO of lab test innovator Guardant Health. Addressing the 2024 Jefferies London Healthcare conference, he said: “The positivity we’ve had on the Average Sales Price (ASP) in the core business could potentially bring that 2028 target forward by maybe one year.”
Guardant Health Eyes Earlier Breakeven As Liquid Biopsy Boosts Outlook
Lab Test Innovator Focuses On US Coverage Gaps
Guardant Health expects to break even by 2028. A positive pricing outlook for the Guardant 360 lab test could bring this forward by maybe one year, CFO Mike Bell told the Jefferies London Healthcare Conference.
